BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

As the global COVID-19 pandemic continues to crater equity markets, buysiders are increasing their cash positions and companies are taking measures to delay any fund-raising activity to 2H20, when capital raises can hopefully be done...
BioCentury | Apr 4, 2020
Translation in Brief

HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath

HiFiBiO’s antibody discovery platform  HiFiBiO Therapeutics has described in a Nature Biotechnology article its CelliGO microfluidics platform for high-throughput screening of antibodies secreted from single B cells. The company is using the platform to screen...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Apr 1, 2020
Product Development

Akero reports positive Phase IIa data for NASH; pandemic delays expansion cohort

Akero gained $4.02 (23%) to $21.20 Tuesday, adding around $115 million in market cap, after reporting that its lead candidate AKR-001 met primary and secondary endpoints in the Phase IIa BALANCED study to treat non-alcoholic...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

Maryland team highlights 17 approved drugs that could be repurposed for COVID-19   A University of Maryland team identified 17 FDA-approved drugs that could be repurposed for COVID-19. Reported in a preprint posted Friday to...
BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

By teaming with Astellas to develop bispecifics for immuno-oncology, CytomX has struck its first major partnership in two-and-a-half years, giving its shares a much-needed boost after a prolonged slump in 2018-19. Astellas Pharma Inc. (Tokyo:4503)...
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Mar 17, 2020
Product Development

Phase II data bring Blueprint closer to major market expansion for Ayvakit

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on...
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

All WuXi AppTec Chinese sites operating  WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) said it has resumed operations at its Wuhan facility, which provides discovery chemistry services. The company has now restarted operations at all its...
Items per page:
1 - 10 of 6561